Takeda Looks To Double Emerging Market Revenues
Focus Will Be On Innovation
Executive Summary
Japanese firm aims for growth ahead of the market as it rolls out global innovative products and its Wave 1 portfolio across emerging markets, aided by "targeted investments".
You may also be interested in...
Takeda Grows Immuno-Oncology Portfolio With $525m Maverick Acquisition
Maverick’s bispecific antibody program adds to Takeda’s expanding immuno-oncology development business, which also includes cell therapy programs.
Takeda Looks To Ride 'Wave 1' To JPY5tn Target
Takeda tries to get investors as excited as it is about the first wave of post-R&D reorganization candidates coming through, as it lays out 'ambitious but achievable' revenue target.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Genmab confident in CD20xCD3 battle; Alzheimer’s disappointment for Roche; Japan speed bump for Shionogi’s oral COVID antiviral; pharma’s view of psychedelics; and a roundup of key BIO sessions.